<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83005">
  <stage>Registered</stage>
  <submitdate>23/07/2008</submitdate>
  <approvaldate>29/08/2008</approvaldate>
  <actrnumber>ACTRN12608000438358</actrnumber>
  <trial_identification>
    <studytitle>Baseline Results and Cost-effectiveness Study - VentrAssist left ventricular assist device</studytitle>
    <scientifictitle>Evaluating the use of the VentrAssist left ventricular assist device (LVAD) in a population with end-stage heart failure with data comparable to published data from similar devices</scientifictitle>
    <utrn />
    <trialacronym>BRACE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>End stage heart failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The VentrAssist left ventricular assist device is an active implantable medical device used to bridge patients (maintain circulatory support) until a donor heart may be found, or may be implanted as destination therapy (for the remainder of the participants life). Patients will be followed up at clinic visits until transplant, explant, death or 24 months post implant. Each visit will take approxiamtely 30-60 minutes to complete.</interventions>
    <comparator>Published data from other left ventricual assist devices. There is no control group for this study.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Actuarial survival for VentrAssist LVAD patients, where patients are censored from the actuarial survival curve on LVAD removal (for heart transplantation or native heart recovery</outcome>
      <timepoint>24 months post device implant</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (serious adverse events). Serious adverse events will be categorised using the Interagency Registry for Mechanical Assisted Circulatory Support (INTERMACS) definitions.</outcome>
      <timepoint>24 months post device implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>New York Heart Association functional status used to categorize heart failure.</outcome>
      <timepoint>24 months post device implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life questionnaire - EUROQOL and SF-36</outcome>
      <timepoint>24 months post device implant</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Economic data - examine the number and duration of hospital addmissions, procedures and medication use as a surrogate measure of cost.</outcome>
      <timepoint>24 months post device implant</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Body surface area equal to or greater than 1.2 meters squared; need for mechanical circulatory support; ability to provide informed consent; ability to perform ongoing functions of device management; age greater than or equal to 18 years of age (French sites only)</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Stroke in the 90 days prior to enrolment or cerebrovascular disease with significant carotid stenosis; chronic renal failure; significant hepatic disease; significant pulmonary disease; clinical signs of systemic infection; fixed right ventricular failure; coagulation systemic disorders; mechanical prosthetic aortic valve; echocardiographic evidence of moderate/sever aortic/tricuspid valve insufficiency; cachexia or clinical signs of severe malnourishment; technically challenging cardiac disease e.g. hypertrophic or restrictive cardiomyopathy; previous heart transplant, cardiomyoplasty or passive restraint device insertion; contraindication to the administration of anticoagulant or antiaggregation agents; psychiatric/psychological disorders likely to impair with protocol compliance or device management; pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>12/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>75</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ventracor Limited</primarysponsorname>
    <primarysponsoraddress>126 Greville Street,
Chatswood, NSW, 2067</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ventracor Limited</fundingname>
      <fundingaddress>126 Greville Street,
Chatswood, NSW, 2067</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The VentrAssist left ventricular assist device will provide circulatory support for patients with end-satge heart failure with results comparable to other left ventricular assist devices</summary>
    <trialwebsite />
    <publication>Poster: An interim review of the Baseline Results and Cost Effectiveness (BRACE) study: VentrAssist Left Ventricular Assist Device. European Society of Cardiology, 16th June 2008, Milan Italy.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Huntingdon Research Ethics Committee</ethicname>
      <ethicaddress>Victoria House
Capitol Park
Fulbourn, Cambridge, CB16X8</ethicaddress>
      <ethicapprovaldate>16/08/2006</ethicapprovaldate>
      <hrec>06/Q0104/77</hrec>
      <ethicsubmitdate>3/07/2006</ethicsubmitdate>
      <ethiccountry>United Kingdom</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John Woodard</name>
      <address>126 Greville Street,
Chatswood, NSW, 2067</address>
      <phone>+61 2 9406 3102</phone>
      <fax />
      <email>john.woodard@ventracor.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Terry McCarthy</name>
      <address>Cereslaan 34
5384 VT
Heesch</address>
      <phone>+31 412 487 140</phone>
      <fax />
      <email>terry.mccarthy@ventracor.com</email>
      <country>Netherlands</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Stefan Czyniewski</name>
      <address>126 Greville Street,
Chatswood, NSW, 2067</address>
      <phone />
      <fax />
      <email>stefan.czyniewski@ventracor.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>